Advertisement

Neonatology pp 2349-2386 | Cite as

Retinopathy of Prematurity

  • José Carlos Rivera
  • Elsa Duchemin-Kermorvant
  • Allison Dorfman
  • Tianwei Ellen Zhou
  • Luis H. Ospina
  • Sylvain Chemtob
Reference work entry

Abstract

Retinopathy of prematurity (ROP) is an ocular disorder that affects the integrity and function of the immature vasculature and neurons of the developing retina. ROP is considered the major cause of visual impairment and blindness in premature infants. This chapter includes a general review of the current knowledge about this disorder including demographic incidence, risk factors, recent observations regarding neurovascular dysfunctions in both the inner and outer immature retina, mechanisms and factors implicated in the pathophysiology of ROP. Finally, recommendations for surveillance and follow-up for ROP, as well as current and future preventive therapeutic strategies to preserve retinal structure and function are discussed.

Notes

Acknowledgments

We thank Drs. Maria Ana Martinez, Daniel Moreno, and Hugo Quiroz of the Association to Prevent Blindness in Mexico (APEC) for the contribution of the pictures in Figs. 3 and 4.

References

  1. Akula JD, Mocko JA, Moskowitz A, Hansen RM, Fulton AB (2007) The oscillatory potentials of the dark-adapted electroretinogram in retinopathy of prematurity. Invest Ophthalmol Vis Sci 48:5788–5797PubMedPubMedCentralCrossRefGoogle Scholar
  2. Alm A, Bill A (1973) Ocular and optic nerve blood flow at normal and increased intraocular pressures in monkeys (macaca irus): a study with radioactively labelled microspheres including flow determinations in brain and some other tissues. Exp Eye Res 15:15–29PubMedCrossRefGoogle Scholar
  3. Alon T, Hemo I, Itin A, Pe’er J, Stone J, Keshet E (1995) Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1:1024–1028CrossRefPubMedGoogle Scholar
  4. An international classification of retinopathy of prematurity (1984) The committee for the classification of retinopathy of prematurity. Arch Ophthalmol 102:1130–1134Google Scholar
  5. Anderson MF, Ramasamy B, Lythgoe DT, Clark D (2014) Choroidal thickness in regressed retinopathy of prematurity. Eye (Lond) 28:1461–1468CrossRefGoogle Scholar
  6. Antonelli-Orlidge A, Saunders KB, Smith SR, D’Amore PA (1989) An activated form of transforming growth factor beta is produced by cocultures of endothelial cells and pericytes. Proc Natl Acad Sci U S A 86:4544–4548PubMedPubMedCentralCrossRefGoogle Scholar
  7. Arnold RW, Kesler K, Avila E (1994) Susceptibility to retinopathy of prematurity in alaskan natives. J Pediatr Ophthalmol Strabismus 31:192–194PubMedGoogle Scholar
  8. Arroe M, Peitersen B (1994) Retinopathy of prematurity: review of a seven-year period in a Danish neonatal intensive care unit. Acta Paediatr 83:501–505PubMedCrossRefGoogle Scholar
  9. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964–967CrossRefPubMedGoogle Scholar
  10. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, Isner JM (1999) Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85:221–228PubMedCrossRefGoogle Scholar
  11. Ashton N (1957) Experimental retrolental fibroplasia. Annu Rev Med 8:441–454PubMedCrossRefGoogle Scholar
  12. Askie LM, Brocklehurst P, Darlow BA, Finer N, Schmidt B, Tarnow-Mordi W (2011) Neoprom: neonatal oxygenation prospective meta-analysis collaboration study protocol. BMC Pediatr 11:6PubMedPubMedCentralCrossRefGoogle Scholar
  13. Atchaneeyasakul LO, Trinavarat A (2010) Choroidal ruptures after adjuvant intravitreal injection of bevacizumab for aggressive posterior retinopathy of prematurity. J Perinatol 30:497–499PubMedCrossRefGoogle Scholar
  14. Autrata R, Krejcirova I, Senkova K, Holousova M, Dolezel Z, Borek I (2012a) Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone i and posterior zone ii. Eur J Ophthalmol 22:687–694PubMedCrossRefGoogle Scholar
  15. Autrata R, Senkova K, Holousova M, Krejcirova I, Dolezel Z, Borek I (2012b) Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone i and posterior zone ii--four years results. Cesk Slov Oftalmol 68:29–36PubMedGoogle Scholar
  16. Banach MJ, Ferrone PJ, Trese MT (2000) A comparison of dense versus less dense diode laser photocoagulation patterns for threshold retinopathy of prematurity. Ophthalmology 107:324–327, discussion 328PubMedCrossRefGoogle Scholar
  17. Berger TM, Rifai N, Avery ME, Frei B (1996) Vitamin c in premature and full-term human neonates. Redox Rep 257–262PubMedCrossRefGoogle Scholar
  18. Binenbaum G, Ying GS, Quinn GE, Huang J, Dreiseitl S, Antigua J, Foroughi N, Abbasi S (2012) The chop postnatal weight gain, birth weight, and gestational age retinopathy of prematurity risk model. Arch Ophthalmol 130:1560–1565PubMedCrossRefGoogle Scholar
  19. Bremer DL, Palmer EA, Fellows RR, Baker JD, Hardy RJ, Tung B, Rogers GL (1998) Strabismus in premature infants in the first year of life. Cryotherapy for retinopathy of prematurity cooperative group. Arch Ophthalmol 116:329–333PubMedCrossRefGoogle Scholar
  20. Brion LP, Bell EF, Raghuveer TS (2003) Vitamin e supplementation for prevention of morbidity and mortality in preterm infants. Cochrane Database Syst Rev CD003665Google Scholar
  21. Brown BA, Thach AB, Song JC, Marx JL, Kwun RC, Frambach DA (1998) Retinopathy of prematurity: evaluation of risk factors. Int Ophthalmol 22:279–283PubMedCrossRefGoogle Scholar
  22. Buss IH, McGill F, Darlow BA, Winterbourn CC (2001) Vitamin c is reduced in human milk after storage. Acta Paediatr 90:813–815PubMedCrossRefGoogle Scholar
  23. Caccavale A, Romanazzi F, Imparato M, Negri A, Morano A, Ferentini F (2011) Central serous chorioretinopathy: a pathogenetic model. Clin Ophthalmol 5:239–243PubMedPubMedCentralCrossRefGoogle Scholar
  24. Campbell K (1951) Intensive oxygen therapy as a possible cause of retrolental fibroplasia; a clinical approach. Med J Aust 2:48–50PubMedGoogle Scholar
  25. Capone AJ, Trese MT, Hartnett ME (2014) Treatment of stages 4 and 5 retinopathy of prematurity. In: Hartnett ME (ed) Pediatric retina, 2nd edn. Lippincott Williams & Wilkins, a Wolters Kluwer Health, Philadelphia, pp 597–603Google Scholar
  26. Carr A, Frei B (1999) Does vitamin c act as a pro-oxidant under physiological conditions? Faseb J 13:1007–1024PubMedCrossRefGoogle Scholar
  27. Checchin D, Sennlaub F, Sirinyan M, Brault S, Zhu T, Kermorvant-Duchemin E, Hardy P, Balazy M, Chemtob S (2006) Hypercapnia prevents neovascularization via nitrative stress. Free Radic Biol Med 40:543–553PubMedCrossRefGoogle Scholar
  28. Chemtob S, Beharry K, Rex J, Chatterjee T, Varma DR, Aranda JV (1991) Ibuprofen enhances retinal and choroidal blood flow autoregulation in newborn piglets. Invest Ophthalmol Vis Sci 32:1799–1807PubMedGoogle Scholar
  29. Chen J, Smith LE (2007) Retinopathy of prematurity. Angiogenesis 10:133–140PubMedCrossRefGoogle Scholar
  30. Chen ML, Guo L, Smith LE, Dammann CE, Dammann O (2010) High or low oxygen saturation and severe retinopathy of prematurity: a meta-analysis. Pediatrics 125:e1483–e1492PubMedPubMedCentralCrossRefGoogle Scholar
  31. Chen YH, Chen SN, Lien RI, Shih CP, Chao AN, Chen KJ, Hwang YS, Wang NK, Chen YP, Lee KH, Chuang CC, Chen TL, Lai CC, Wu WC (2014) Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes. Eye (Lond) 28:1080–1086, quiz 1087CrossRefGoogle Scholar
  32. Choi MY, Park IK, Yu YS (2000) Long term refractive outcome in eyes of preterm infants with and without retinopathy of prematurity: comparison of keratometric value, axial length, anterior chamber depth, and lens thickness. Br J Ophthalmol 84:138–143PubMedPubMedCentralCrossRefGoogle Scholar
  33. Chow DR, Ferrone PJ, Trese MT (1998) Refractive changes associated with scleral buckling and division in retinopathy of prematurity. Arch Ophthalmol 116:1446–1448PubMedCrossRefGoogle Scholar
  34. Chow LC, Wright KW, Sola A (2003) Can changes in clinical practice decrease the incidence of severe retinopathy of prematurity in very low birth weight infants? Pediatrics 111:339–345CrossRefPubMedGoogle Scholar
  35. Clark D, Mandal K (2008) Treatment of retinopathy of prematurity. Early Hum Dev 84:95–99PubMedCrossRefGoogle Scholar
  36. Connolly BP, Ng EY, McNamara JA, Regillo CD, Vander JF, Tasman W (2002) A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 2. Refractive outcome. Ophthalmology 109:936–941PubMedCrossRefGoogle Scholar
  37. Connor KM, SanGiovanni JP, Lofqvist C, Aderman CM, Chen J, Higuchi A, Hong S, Pravda EA, Majchrzak S, Carper D, Hellstrom A, Kang JX, Chew EY, Salem N Jr, Serhan CN, Smith LE (2007) Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med 13:868–873PubMedPubMedCentralCrossRefGoogle Scholar
  38. Cringle SJ, Yu PK, Su EN, Yu DY (2006) Oxygen distribution and consumption in the developing rat retina. Invest Ophthalmol Vis Sci 47:4072–4076PubMedCrossRefGoogle Scholar
  39. Cryotherapy for Retinopathy of Prematurity Cooperative Group (1988) Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Arch Ophthalmol 106:471–479CrossRefGoogle Scholar
  40. Cryotherapy for Retinopathy of Prematurity Cooperative Group (1994) The natural ocular outcome of premature birth and retinopathy. Status at 1 year. Arch Ophthalmol 112:903–912CrossRefGoogle Scholar
  41. Cryotherapy for Retinopathy of Prematurity Cooperative Group (2001a) Effect of retinal ablative therapy for threshold retinopathy of prematurity: results of goldmann perimetry at the age of 10 years. Arch Ophthalmol 119:1120–1125CrossRefGoogle Scholar
  42. Cryotherapy for Retinopathy of Prematurity Cooperative Group (2001b) Multicenter trial of cryotherapy for retinopathy of prematurity: ophthalmological outcomes at 10 years. Arch Ophthalmol 119:1110–1118CrossRefGoogle Scholar
  43. Csak K, Szabo V, Szabo A, Vannay A (2006) Pathogenesis and genetic basis for retinopathy of prematurity. Front Biosci 11:908–920PubMedCrossRefGoogle Scholar
  44. Cusick M, Charles MK, Agron E, Sangiovanni JP, Ferris FL 3rd, Charles S (2006) Anatomical and visual results of vitreoretinal surgery for stage 5 retinopathy of prematurity. Retina 26:729–735PubMedCrossRefGoogle Scholar
  45. Darlow BA, Buss H, McGill F, Fletcher L, Graham P, Winterbourn CC (2005) Vitamin c supplementation in very preterm infants: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed 90:F117–F122PubMedPubMedCentralCrossRefGoogle Scholar
  46. Davitt BV, Wallace DK (2009) Plus disease. Surv Ophthalmol 54:663–670PubMedCrossRefGoogle Scholar
  47. Davitt BV, Dobson V, Good WV, Hardy RJ, Quinn GE, Siatkowski RM, Summers CG, Tung B (2005) Prevalence of myopia at 9 months in infants with high-risk prethreshold retinopathy of prematurity. Ophthalmology 112:1564–1568PubMedCrossRefGoogle Scholar
  48. Davitt BV, Dobson V, Quinn GE, Hardy RJ, Tung B, Good WV (2009) Astigmatism in the early treatment for retinopathy of prematurity study: findings to 3 years of age. Ophthalmology 116:332–339PubMedCrossRefGoogle Scholar
  49. Davitt BV, Quinn GE, Wallace DK, Dobson V, Hardy RJ, Tung B, Lai D, Good WV (2011) Astigmatism progression in the early treatment for retinopathy of prematurity study to 6 years of age. Ophthalmology 118:2326–2329PubMedPubMedCentralCrossRefGoogle Scholar
  50. Delport SD, Swanepoel JC, Odendaal PJ, Roux P (2002) Incidence of retinopathy of prematurity in very-low-birth-weight infants born at kalafong hospital, pretoria. S Afr Med J 92:986–990PubMedGoogle Scholar
  51. Deulofeut R, Critz A, Adams-Chapman I, Sola A (2006) Avoiding hyperoxia in infants < or = 1250 g is associated with improved short- and long-term outcomes. J Perinatol 26:700–705CrossRefPubMedGoogle Scholar
  52. Dixon JA, Oliver SC, Olson JL, Mandava N (2009) Vegf trap-eye for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drugs 18:1573–1580PubMedCrossRefGoogle Scholar
  53. Dorfman A, Dembinska O, Chemtob S, Lachapelle P (2008) Early manifestations of postnatal hyperoxia on the retinal structure and function of the neonatal rat. Invest Ophthalmol Vis Sci 49:458–466PubMedCrossRefGoogle Scholar
  54. Dorfman AL, Polosa A, Joly S, Chemtob S, Lachapelle P (2009) Functional and structural changes resulting from strain differences in the rat model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 50:2436–2450PubMedCrossRefGoogle Scholar
  55. Drack A (2006) Retinopathy of prematurity. Adv Pediatr 53:211–226PubMedCrossRefGoogle Scholar
  56. Drenser K, Girach A, Capone A (2016) A randomized, placebo-controlled study of intravitreal ocriplasmin in pediatric patients scheduled for vitrectomy. Retina 36:565–575PubMedCrossRefGoogle Scholar
  57. Early Treatment for Retinopathy of Prematurity Cooperative Group (2003) Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 121:1684–1694CrossRefGoogle Scholar
  58. Eckert GU, Fortes Filho JB, Maia M, Procianoy RS (2012) A predictive score for retinopathy of prematurity in very low birth weight preterm infants. Eye (Lond) 26:400–406CrossRefGoogle Scholar
  59. Ecsedy M, Szamosi A, Karko C, Zubovics L, Varsanyi B, Nemeth J, Recsan Z (2007) A comparison of macular structure imaged by optical coherence tomography in preterm and full-term children. Invest Ophthalmol Vis Sci 48:5207–5211PubMedCrossRefGoogle Scholar
  60. Ecsedy M, Varsanyi B, Szigeti A, Szrnka G, Nemeth J, Recsan Z (2011) Cone function in children with a history of preterm birth. Doc Ophthalmol 122:141–148PubMedCrossRefGoogle Scholar
  61. Ells A, Hicks M, Fielden M, Ingram A (2005) Severe retinopathy of prematurity: longitudinal observation of disease and screening implications. Eye (Lond) 19:138–144CrossRefGoogle Scholar
  62. Ells A, Guernsey DL, Wallace K, Zheng B, Vincer M, Allen A, Ingram A, DaSilva O, Siebert L, Sheidow T, Beis J, Robitaille JM (2010) Severe retinopathy of prematurity associated with fzd4 mutations. Ophthalmic Genet 31:37–43PubMedCrossRefGoogle Scholar
  63. Engin KN (2009) Alpha-tocopherol: looking beyond an antioxidant. Mol Vis 15:855–860PubMedPubMedCentralGoogle Scholar
  64. Ferrara N, Damico L, Shams N, Lowman H, Kim R (2006) Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26:859–870PubMedCrossRefGoogle Scholar
  65. Ferrone PJ, Harrison C, Trese MT (1997) Lens clarity after lens-sparing vitrectomy in a pediatric population. Ophthalmology 104:273–278PubMedCrossRefGoogle Scholar
  66. Fielder AR, Shaw DE, Robinson J, Ng YK (1992) Natural history of retinopathy of prematurity: a prospective study. Eye (Lond) 6(Pt 3):233–242CrossRefGoogle Scholar
  67. Fierson WM (2013) Screening examination of premature infants for retinopathy of prematurity. Pediatrics 131:189–195PubMedCrossRefGoogle Scholar
  68. Fierson WM, Capone A Jr (2015) Telemedicine for evaluation of retinopathy of prematurity. Pediatrics 135:e238–e254PubMedCrossRefGoogle Scholar
  69. Foster PJ, Jiang Y (2014) Epidemiology of myopia. Eye (Lond) 28:202–208CrossRefGoogle Scholar
  70. Fulton AB, Hansen RM (1995) Electroretinogram responses and refractive errors in patients with a history of retinopathy prematurity. Doc Ophthalmol 91:87–100PubMedCrossRefGoogle Scholar
  71. Fulton AB, Hansen RM (1996) Photoreceptor function in infants and children with a history of mild retinopathy of prematurity. J Opt Soc Am A Opt Image Sci Vis 13:566–571PubMedCrossRefGoogle Scholar
  72. Fulton AB, Hansen RM, Petersen RA, Vanderveen DK (2001) The rod photoreceptors in retinopathy of prematurity: an electroretinographic study. Arch Ophthalmol 119:499–505PubMedCrossRefGoogle Scholar
  73. Fulton AB, Hansen RM, Moskowitz A, Barnaby AM (2005) Multifocal erg in subjects with a history of retinopathy of prematurity. Doc Ophthalmol 111:7–13PubMedCrossRefGoogle Scholar
  74. Fulton AB, Hansen RM, Moskowitz A (2008) The cone electroretinogram in retinopathy of prematurity. Invest Ophthalmol Vis Sci 49:814–819PubMedPubMedCentralCrossRefGoogle Scholar
  75. Fulton AB, Hansen RM, Moskowitz A (2009) Development of rod function in term born and former preterm subjects. Optom Vis Sci 86:E653–E658PubMedPubMedCentralCrossRefGoogle Scholar
  76. Gallo JE, Jacobson L, Broberger U (1993) Perinatal factors associated with retinopathy of prematurity. Acta Paediatr 82:829–834PubMedCrossRefGoogle Scholar
  77. Geloneck MM, Chuang AZ, Clark WL, Hunt MG, Norman AA, Packwood EA, Tawansy KA, Mintz-Hittner HA (2014) Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol 132:1327–1333PubMedCrossRefGoogle Scholar
  78. Gilbert C (2008) Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev 84:77–82PubMedCrossRefGoogle Scholar
  79. Gilbert C, Rahi J, Eckstein M, O'Sullivan J, Foster A (1997) Retinopathy of prematurity in middle-income countries. Lancet 350:12–14PubMedCrossRefGoogle Scholar
  80. Gilbert C, Fielder A, Gordillo L, Quinn G, Semiglia R, Visintin P, Zin A (2005) Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs. Pediatrics 115:e518–e525PubMedCrossRefGoogle Scholar
  81. Goggin M, O’Keefe M (1993) Diode laser for retinopathy of prematurity–early outcome. Br J Ophthalmol 77:559–562PubMedPubMedCentralCrossRefGoogle Scholar
  82. Good WV (2004) Final results of the early treatment for retinopathy of prematurity (etrop) randomized trial. Trans Am Ophthalmol Soc 102:233–248, discussion 248–250PubMedPubMedCentralGoogle Scholar
  83. Good WV, Hardy RJ, Dobson V, Palmer EA, Phelps DL, Quintos M, Tung B (2005) The incidence and course of retinopathy of prematurity: findings from the early treatment for retinopathy of prematurity study. Pediatrics 116:15–23PubMedCrossRefGoogle Scholar
  84. Good WV, Hardy RJ, Dobson V, Palmer EA, Phelps DL, Tung B, Redford M (2010) Final visual acuity results in the early treatment for retinopathy of prematurity study. Arch Ophthalmol 128:663–671PubMedCrossRefGoogle Scholar
  85. Greene HL, Porchelli P, Adcock E, Swift L (1992) Vitamins for newborn infant formulas: a review of recommendations with emphasis on data from low birth-weight infants. Eur J Clin Nutr 46(Suppl 4):S1–S8PubMedGoogle Scholar
  86. Gu X, Samuel S, El-Shabrawey M, Caldwell RB, Bartoli M, Marcus DM, Brooks SE (2002) Effects of sustained hyperoxia on revascularization in experimental retinopathy of prematurity. Invest Ophthalmol Vis Sci 43:496–502PubMedGoogle Scholar
  87. Hack M, Taylor HG, Klein N, Eiben R, Schatschneider C, Mercuri-Minich N (1994) School-age outcomes in children with birth weights under 750 g. N Engl J Med 331:753–759PubMedCrossRefGoogle Scholar
  88. Haddad MA, Sei M, Sampaio MW, Kara-Jose N (2007) Causes of visual impairment in children: a study of 3,210 cases. J Pediatr Ophthalmol Strabismus 44:232–240PubMedGoogle Scholar
  89. Halliwell B (1996) Vitamin c: antioxidant or pro-oxidant in vivo? Free Radic Res 25:439–454PubMedCrossRefGoogle Scholar
  90. Hamil BM, Munks B et al (1947) Vitamin c in the blood and urine of the newborn and in the cord and maternal blood. Am J Dis Child 74:417–433PubMedGoogle Scholar
  91. Hammer DX, Iftimia NV, Ferguson RD, Bigelow CE, Ustun TE, Barnaby AM, Fulton AB (2008) Foveal fine structure in retinopathy of prematurity: an adaptive optics fourier domain optical coherence tomography study. Invest Ophthalmol Vis Sci 49:2061–2070PubMedPubMedCentralCrossRefGoogle Scholar
  92. Hansen RM, Fulton AB (2000) Background adaptation in children with a history of mild retinopathy of prematurity. Invest Ophthalmol Vis Sci 41:320–324PubMedGoogle Scholar
  93. Hansen RM, Harris ME, Moskowitz A, Fulton AB (2010) Deactivation of the rod response in retinopathy of prematurity. Doc Ophthalmol 121:29–35PubMedPubMedCentralCrossRefGoogle Scholar
  94. Hard AL, Hellstrom A (2011) On the use of antiangiogenetic medications for retinopathy of prematurity. Acta Paediatr 100:1063–1065PubMedPubMedCentralCrossRefGoogle Scholar
  95. Harder BC, Schlichtenbrede FC, von Baltz S, Jendritza W, Jendritza B, Jonas JB (2013) Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. Am J Ophthalmol 155:1119–1124 e1111PubMedCrossRefGoogle Scholar
  96. Hardy P, Abran D, Li DY, Fernandez H, Varma DR, Chemtob S (1994) Free radicals in retinal and choroidal blood flow autoregulation in the piglet: interaction with prostaglandins. Invest Ophthalmol Vis Sci 35:580–591PubMedGoogle Scholar
  97. Hardy P, Nuyt AM, Abran D, St-Louis J, Varma DR, Chemtob S (1996a) Nitric oxide in retinal and choroidal blood flow autoregulation in newborn pigs: Interactions with prostaglandins. Pediatr Res 39:487–493PubMedCrossRefGoogle Scholar
  98. Hardy P, Peri KG, Lahaie I, Varma DR, Chemtob S (1996b) Increased nitric oxide synthesis and action preclude choroidal vasoconstriction to hyperoxia in newborn pigs. Circ Res 79:504–511PubMedCrossRefGoogle Scholar
  99. Harris ME, Moskowitz A, Fulton AB, Hansen RM (2011) Long-term effects of retinopathy of prematurity (rop) on rod and rod-driven function. Doc Ophthalmol 122:19–27PubMedCrossRefGoogle Scholar
  100. Hartnett ME, Maguluri S, Thompson HW, McColm JR (2004) Comparison of retinal outcomes after scleral buckle or lens-sparing vitrectomy for stage 4 retinopathy of prematurity. Retina 24:753–757PubMedCrossRefGoogle Scholar
  101. Hellgren G, Lofqvist C, Hard AL, Hansen-Pupp I, Gram M, Ley D, Smith LE, Hellstrom A (2016) Serum concentrations of vascular endothelial growth factor in relation to retinopathy of prematurity. Pediatr Res 79:70–75PubMedPubMedCentralCrossRefGoogle Scholar
  102. Hellstrom A, Perruzzi C, Ju M, Engstrom E, Hard AL, Liu JL, Albertsson-Wikland K, Carlsson B, Niklasson A, Sjodell L, LeRoith D, Senger DR, Smith LE (2001) Low igf-i suppresses vegf-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci U S A 98:5804–5808PubMedPubMedCentralCrossRefGoogle Scholar
  103. Hellstrom A, Hard AL, Engstrom E, Niklasson A, Andersson E, Smith L, Lofqvist C (2009) Early weight gain predicts retinopathy in preterm infants: new, simple, efficient approach to screening. Pediatrics 123:e638–e645PubMedCrossRefGoogle Scholar
  104. Hiraoka M, Berinstein DM, Trese MT, Shastry BS (2001) Insertion and deletion mutations in the dinucleotide repeat region of the norrie disease gene in patients with advanced retinopathy of prematurity. J Hum Genet 46:178–181PubMedCrossRefGoogle Scholar
  105. Hittner HM, Rudolph AJ, Kretzer FL (1984) Suppression of severe retinopathy of prematurity with vitamin e supplementation ultrastructural mechanism of clinical efficacy. Ophthalmology 91:1512–1523PubMedCrossRefGoogle Scholar
  106. Hoerster R, Muether P, Dahlke C, Mehler K, Oberthur A, Kirchhof B, Fauser S (2013) Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity. Acta Ophthalmol 91:e74–e75PubMedCrossRefGoogle Scholar
  107. Holmes JM, Zhang S, Leske DA, Lanier WL (1998) Carbon dioxide-induced retinopathy in the neonatal rat. Curr Eye Res 17:608–616PubMedPubMedCentralCrossRefGoogle Scholar
  108. Hong YR, Kim YH, Kim SY, Nam GY, Cheon HJ, Lee SJ (2015) Plasma concentrations of vascular endothelial growth factor in retinopathy of prematurity after intravitreal bevacizumab injection. Retina 35:1772–1777PubMedCrossRefGoogle Scholar
  109. Hu J, Blair MP, Shapiro MJ, Lichtenstein SJ, Galasso JM, Kapur R (2012) Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol 130:1000–1006PubMedCrossRefGoogle Scholar
  110. Hubbard GB 3rd (2008) Surgical management of retinopathy of prematurity. Curr Opin Ophthalmol 19:384–390PubMedPubMedCentralCrossRefGoogle Scholar
  111. Husain SM, Sinha AK, Bunce C, Arora P, Lopez W, Mun KS, Reddy MA, Adams GG (2013) Relationships between maternal ethnicity, gestational age, birth weight, weight gain, and severe retinopathy of prematurity. J Pediatr 163:67–72PubMedCrossRefGoogle Scholar
  112. Hwang CK, Hubbard GB, Hutchinson AK, Lambert SR (2015) Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis. Ophthalmology 122:1008–1015PubMedPubMedCentralCrossRefGoogle Scholar
  113. Ingalls TH, Draper R, Teel HM (1938) Vitamin c in human pregnancy and lactation. II. Studies during lactation. Am J Dis Child 56:1011–1019CrossRefGoogle Scholar
  114. Jacobson RM, Feinstein AR (1992) Oxygen as a cause of blindness in premature infants: “autopsy” of a decade of errors in clinical epidemiologic research. J Clin Epidemiol 45:1265–1287PubMedCrossRefGoogle Scholar
  115. Jalali S, Balakrishnan D, Zeynalova Z, Padhi TR, Rani PK (2013) Serious adverse events and visual outcomes of rescue therapy using adjunct bevacizumab to laser and surgery for retinopathy of prematurity. The Indian twin cities retinopathy of prematurity screening database report number 5. Arch Dis Child Fetal Neonatal Ed 98:F327–F333PubMedCrossRefGoogle Scholar
  116. Johnson BA, Weil MH (1991) Redefining ischemia due to circulatory failure as dual defects of oxygen deficits and of carbon dioxide excesses. Crit Care Med 19:1432–1438PubMedCrossRefGoogle Scholar
  117. Johnson L, Schaffer D, Boggs TR Jr (1974) The premature infant, vitamin e deficiency and retrolental fibroplasia. Am J Clin Nutr 27:1158–1173PubMedCrossRefGoogle Scholar
  118. Johnson L, Schaffer D, Quinn G, Goldstein D, Mathis MJ, Otis C, Boggs TR Jr (1982) Vitamin e supplementation and the retinopathy of prematurity. Ann N Y Acad Sci 393:473–495PubMedCrossRefGoogle Scholar
  119. Kaiser RS, Trese MT (2001) Iris atrophy, cataracts, and hypotony following peripheral ablation for threshold retinopathy of prematurity. Arch Ophthalmol 119:615–617PubMedCrossRefGoogle Scholar
  120. Kinsey VE (1956) Retrolental fibroplasia; cooperative study of retrolental fibroplasia and the use of oxygen. AMA Arch Ophthalmol 56:481–543PubMedCrossRefGoogle Scholar
  121. Kizawa J, Machida S, Kobayashi T, Gotoh Y, Kurosaka D (2006) Changes of oscillatory potentials and photopic negative response in patients with early diabetic retinopathy. Jpn J Ophthalmol 50:367–373PubMedCrossRefGoogle Scholar
  122. Klufas MA, Chan RV (2015) Intravitreal anti-vegf therapy as a treatment for retinopathy of prematurity: what we know after 7 years. J Pediatr Ophthalmol Strabismus 52:77–84PubMedCrossRefGoogle Scholar
  123. Knight-Nanan DM, O’Keefe M (1996) Refractive outcome in eyes with retinopathy of prematurity treated with cryotherapy or diode laser: 3 year follow up. Br J Ophthalmol 80:998–1001PubMedPubMedCentralCrossRefGoogle Scholar
  124. Kobayashi Y, Yokoi T, Yokoi T, Hiraoka M, Nishina S, Azuma N (2011) Fluorescein staining of the vitreous during vitrectomy for retinopathy of prematurity. Retina 31:1717–1719PubMedCrossRefGoogle Scholar
  125. Kong L, Mintz-Hittner HA, Penland RL, Kretzer FL, Chevez-Barrios P (2008) Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study. Arch Ophthalmol 126:1161–1163PubMedCrossRefGoogle Scholar
  126. Kong L, Bhatt AR, Demny AB, Coats DK, Li A, Rahman EZ, Smith OE, Steinkuller PG (2015) Pharmacokinetics of bevacizumab and its effects on serum vegf and igf-1 in infants with retinopathy of prematurity. Invest Ophthalmol Vis Sci 56:956–961PubMedCrossRefGoogle Scholar
  127. Kretzer FL, Mehta RS, Johnson AT, Hunter DG, Brown ES, Hittner HM (1984) Vitamin e protects against retinopathy of prematurity through action on spindle cells. Nature 309:793–795PubMedCrossRefGoogle Scholar
  128. Kychenthal A, Dorta P, Katz X (2006) Zone i retinopathy of prematurity: clinical characteristics and treatment outcomes. Retina 26:S11–S15PubMedCrossRefGoogle Scholar
  129. Lad EM, Hernandez-Boussard T, Morton JM, Moshfeghi DM (2009) Incidence of retinopathy of prematurity in the united states: 1997 through 2005. Am J Ophthalmol 148:451–458PubMedCrossRefGoogle Scholar
  130. Lai AKW, Fu ZJ, Lo AC (2013) Stem cell therapy for retinopathy of prematurity. Anat Physiol 3:126Google Scholar
  131. Lakhanpal RR, Fortun JA, Chan-Kai B, Holz ER (2006) Lensectomy and vitrectomy with and without intravitreal triamcinolone acetonide for vascularly active stage 5 retinal detachments in retinopathy of prematurity. Retina 26:736–740PubMedCrossRefGoogle Scholar
  132. Lang DM, Blackledge J, Arnold RW (2005) Is pacific race a retinopathy of prematurity risk factor? Arch Pediatr Adolesc Med 159:771–773PubMedCrossRefGoogle Scholar
  133. Lanman JT, Guy LP, Dancis J (1954) Retrolental fibroplasia and oxygen therapy. J Am Med Assoc 155:223–226PubMedCrossRefGoogle Scholar
  134. Laser ROP Study Group (1994) Laser therapy for retinopathy of prematurity. Arch Ophthalmol 112:154–156Google Scholar
  135. Laws F, Laws D, Clark D (1997) Cryotherapy and laser treatment for acute retinopathy of prematurity: refractive outcomes, a longitudinal study. Br J Ophthalmol 81:12–15PubMedPubMedCentralCrossRefGoogle Scholar
  136. Linsenmeier RA, Padnick-Silver L (2000) Metabolic dependence of photoreceptors on the choroid in the normal and detached retina. Invest Ophthalmol Vis Sci 41:3117–3123PubMedGoogle Scholar
  137. Lofqvist C, Andersson E, Sigurdsson J, Engstrom E, Hard AL, Niklasson A, Smith LE, Hellstrom A (2006) Longitudinal postnatal weight and insulin-like growth factor i measurements in the prediction of retinopathy of prematurity. Arch Ophthalmol 124:1711–1718PubMedCrossRefGoogle Scholar
  138. Lutty GA, McLeod DS, Bhutto I, Wiegand SJ (2011) Effect of vegf trap on normal retinal vascular development and oxygen-induced retinopathy in the dog. Invest Ophthalmol Vis Sci 52:4039–4047PubMedPubMedCentralCrossRefGoogle Scholar
  139. Machalinska A, Modrzejewska M, Kotowski M, Dziedziejko V, Kucia M, Kawa M, Safranow K, Baskiewicz-Masiuk M, Modrzejewska A, Karczewicz D, Rudnicki J, Machalinski B (2010) Circulating stem cell populations in preterm infants: implications for the development of retinopathy of prematurity. Arch Ophthalmol 128:1311–1319PubMedCrossRefGoogle Scholar
  140. Machalinska A, Kotowski M, Safranow K, Lewandowska J, Modrzejewska M, Rudnicki J, Czajka R, Machalinski B (2011) The role of circulating endothelial progenitor cells in the progression of retinopathy of prematurity–a prospective study. Klin Oczna 113:223–227PubMedGoogle Scholar
  141. Machalinska A, Modrzejewska M, Kawa M, Paczkowska E, Dziedziejko V, Safranow K, Lubinski W, Machalinski B (2013) Potential contribution of mobilized circulating endothelial progenitor cells to development of retinal neovascularization in preterm infants with rop. Klin Oczna 115:194–198PubMedGoogle Scholar
  142. Mactier H, Bradnam MS, Hamilton R (2013) Dark-adapted oscillatory potentials in preterm infants with and without retinopathy of prematurity. Doc Ophthalmol 127:33–40PubMedCrossRefGoogle Scholar
  143. Maida JM, Mathers K, Alley CL (2008) Pediatric ophthalmology in the developing world. Curr Opin Ophthalmol 19:403–408PubMedCrossRefGoogle Scholar
  144. McLoone E, O’Keefe M, McLoone S, Lanigan B (2006) Long term functional and structural outcomes of laser therapy for retinopathy of prematurity. Br J Ophthalmol 90:754–759PubMedPubMedCentralCrossRefGoogle Scholar
  145. McNamara JA (1993) Laser treatment for retinopathy of prematurity. Curr Opin Ophthalmol 4:76–80PubMedCrossRefGoogle Scholar
  146. Michaelson I (1948) The mode of development of the vascular system of the retina, with some observations on its significance for certain retinal diseases. Trans Ophthalmol Soc UK 68:137–180Google Scholar
  147. Micieli JA, Surkont M, Smith AF (2009) A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity. Am J Ophthalmol 148:536–543 e532PubMedCrossRefGoogle Scholar
  148. Mintz-Hittner HA, Kennedy KA, Chuang AZ (2011) Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 364:603–615PubMedPubMedCentralCrossRefGoogle Scholar
  149. Moison RM, van Zoeren-Grobben D, Haasnoot AA et al (1995) Early biochemical detection of bronchopulmonary dysplasia (bpd) in preterm babies [abstract]. Pediatr Res 37:43AGoogle Scholar
  150. Moja L, Lucenteforte E, Kwag KH, Bertele V, Campomori A, Chakravarthy U, D’Amico R, Dickersin K, Kodjikian L, Lindsley K, Loke Y, Maguire M, Martin DF, Mugelli A, Muhlbauer B, Puntmann I, Reeves B, Rogers C, Schmucker C, Subramanian ML, Virgili G (2014) Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database Syst Rev 9:CD011230PubMedCentralGoogle Scholar
  151. Mordenti J, Cuthbertson RA, Ferrara N, Thomsen K, Berleau L, Licko V, Allen PC, Valverde CR, Meng YG, Fei DT, Fourre KM, Ryan AM (1999) Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125i-labeled full-length and fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 27:536–544PubMedCrossRefGoogle Scholar
  152. Muller DP (1992) Vitamin e therapy in retinopathy of prematurity. Eye (Lond) 6(Pt 2):221–225CrossRefGoogle Scholar
  153. Multicenter trial of cryotherapy for retinopathy of prematurity (1998) Preliminary results. Cryotherapy for retinopathy of prematurity cooperative group. Arch Ophthalmol 106:471–479Google Scholar
  154. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z (1999) Vascular endothelial growth factor (vegf) and its receptors. Faseb J 13:9–22PubMedCrossRefGoogle Scholar
  155. Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, Adamis AP (2006) Pegaptanib, a targeted anti-vegf aptamer for ocular vascular disease. Nat Rev Drug Discov 5:123–132PubMedCrossRefGoogle Scholar
  156. Nielsen JC, Naash MI, Anderson RE (1988) The regional distribution of vitamins e and c in mature and premature human retinas. Invest Ophthalmol Vis Sci 29:22–26PubMedGoogle Scholar
  157. Nudleman E, Robinson J, Rao P, Drenser KA, Capone A, Trese MT (2015) Long-term outcomes on lens clarity after lens-sparing vitrectomy for retinopathy of prematurity. Ophthalmology 122:755–759PubMedCrossRefGoogle Scholar
  158. Nutrient needs and feeding of premature infants. Nutrition committee, Canadian Paediatric Society. CMAJ 152:1765–1785 (1995)Google Scholar
  159. O’Connor AR, Stephenson T, Johnson A, Tobin MJ, Moseley MJ, Ratib S, Ng Y, Fielder AR (2002) Long-term ophthalmic outcome of low birth weight children with and without retinopathy of prematurity. Pediatrics 109:12–18PubMedCrossRefGoogle Scholar
  160. O’Connor AR, Stephenson TJ, Johnson A, Tobin MJ, Ratib S, Moseley M, Fielder AR (2004) Visual function in low birthweight children. Br J Ophthalmol 88:1149–1153PubMedPubMedCentralCrossRefGoogle Scholar
  161. O’Connor AR, Stewart CE, Singh J, Fielder AR (2006) Do infants of birth weight less than 1500 g require additional long term ophthalmic follow up? Br J Ophthalmol 90:451–455PubMedPubMedCentralCrossRefGoogle Scholar
  162. O’Connor AR, Wilson CM, Fielder AR (2007) Ophthalmological problems associated with preterm birth. Eye (Lond) 21:1254–1260CrossRefGoogle Scholar
  163. Ospina LH, Lyons CJ, Matsuba C, Jan J, McCormick AQ (2005) Argon laser photocoagulation for retinopathy of prematurity: long-term outcome. Eye (Lond) 19:1213–1218CrossRefGoogle Scholar
  164. Owens WC, Owens EU (1949) Retrolental fibroplasia in premature infants; studies on the prophylaxis of the disease; the use of alpha tocopheryl acetate. Am J Ophthalmol 32:1631–1637PubMedCrossRefGoogle Scholar
  165. Ozaki H, Yu AY, Della N, Ozaki K, Luna JD, Yamada H, Hackett SF, Okamoto N, Zack DJ, Semenza GL, Campochiaro PA (1999) Hypoxia inducible factor-1 alpha is increased in ischemic retina: temporal and spatial correlation with vegf expression. Invest Ophthalmol Vis Sci 40:182–189PubMedGoogle Scholar
  166. Palmer EA, Flynn JT, Hardy RJ, Phelps DL, Phillips CL, Schaffer DB, Tung B (1991) Incidence and early course of retinopathy of prematurity. The cryotherapy for retinopathy of prematurity cooperative group. Ophthalmology 98:1628–1640PubMedCrossRefGoogle Scholar
  167. Palmer EA, Hardy RJ, Dobson V, Phelps DL, Quinn GE, Summers CG, Krom CP, Tung B (2005) 15-year outcomes following threshold retinopathy of prematurity: final results from the multicenter trial of cryotherapy for retinopathy of prematurity. Arch Ophthalmol 123:311–318PubMedCrossRefGoogle Scholar
  168. Penn JS, Tolman BL, Henry MM (1994) Oxygen-induced retinopathy in the rat: relationship of retinal nonperfusion to subsequent neovascularization. Invest Ophthalmol Vis Sci 35:3429–3435PubMedGoogle Scholar
  169. Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME (2008) Vascular endothelial growth factor in eye disease. Prog Retin Eye Res 27:331–371PubMedPubMedCentralCrossRefGoogle Scholar
  170. Pertl L, Steinwender G, Mayer C, Hausberger S, Poschl EM, Wackernagel W, Wedrich A, El-Shabrawi Y, Haas A (2015) A systematic review and meta-analysis on the safety of vascular endothelial growth factor (vegf) inhibitors for the treatment of retinopathy of prematurity. PLoS One 10:e0129383PubMedPubMedCentralCrossRefGoogle Scholar
  171. Phelps DL, Rosenbaum AL, Isenberg SJ, Leake RD, Dorey FJ (1987) Tocopherol efficacy and safety for preventing retinopathy of prematurity: a randomized, controlled, double-masked trial. Pediatrics 79:489–500PubMedGoogle Scholar
  172. Pournaras CJ, Riva CE, Tsacopoulos M, Strommer K (1989) Diffusion of o2 in the retina of anesthetized miniature pigs in normoxia and hyperoxia. Exp Eye Res 49:347–360PubMedCrossRefGoogle Scholar
  173. Proteggente AR, England TG, Rice-Evans CA, Halliwell B (2001) Iron supplementation and oxidative damage to DNA in healthy individuals with high plasma ascorbate. Biochem Biophys Res Commun 288:245–251PubMedCrossRefGoogle Scholar
  174. Provis JM, Leech J, Diaz CM, Penfold PL, Stone J, Keshet E (1997) Development of the human retinal vasculature: cellular relations and vegf expression. Exp Eye Res 65:555–568PubMedCrossRefGoogle Scholar
  175. Qawasmi A, Landeros-Weisenberger A, Bloch MH (2013) Meta-analysis of lcpufa supplementation of infant formula and visual acuity. Pediatrics 131:e262–e272PubMedPubMedCentralCrossRefGoogle Scholar
  176. Quinn GE, Dobson V, Repka MX, Reynolds J, Kivlin J, Davis B, Buckley E, Flynn JT, Palmer EA (1992) Development of myopia in infants with birth weights less than 1251 grams. The cryotherapy for retinopathy of prematurity cooperative group. Ophthalmology 99:329–340PubMedCrossRefGoogle Scholar
  177. Quinn GE, Dobson V, Kivlin J, Kaufman LM, Repka MX, Reynolds JD, Gordon RA, Hardy RJ, Tung B, Stone RA (1998) Prevalence of myopia between 3 months and 5 1/2 years in preterm infants with and without retinopathy of prematurity. Cryotherapy for retinopathy of prematurity cooperative group. Ophthalmology 105:1292–1300PubMedCrossRefGoogle Scholar
  178. Quinn GE, Dobson V, Davitt BV, Hardy RJ, Tung B, Pedroza C, Good WV (2008) Progression of myopia and high myopia in the early treatment for retinopathy of prematurity study: findings to 3 years of age. Ophthalmology 115:1058–1064 e1051PubMedCrossRefGoogle Scholar
  179. Quinn GE, Dobson V, Hardy RJ, Tung B, Palmer EA, Good WV (2011) Visual field extent at 6 years of age in children who had high-risk prethreshold retinopathy of prematurity. Arch Ophthalmol 129:127–132PubMedCrossRefGoogle Scholar
  180. Quinn GE, Dobson V, Davitt BV, Wallace DK, Hardy RJ, Tung B, Lai D, Good WV (2013) Progression of myopia and high myopia in the early treatment for retinopathy of prematurity study: findings at 4 to 6 years of age. J AAPOS 17:124–128PubMedPubMedCentralCrossRefGoogle Scholar
  181. Quinn GE, Ying GS, Daniel E, Hildebrand PL, Ells A, Baumritter A, Kemper AR, Schron EB, Wade K (2014) Validity of a telemedicine system for the evaluation of acute-phase retinopathy of prematurity. JAMA Ophthalmol 132:1178–1184PubMedCrossRefGoogle Scholar
  182. Raju TN, Langenberg P, Bhutani V, Quinn GE (1997) Vitamin e prophylaxis to reduce retinopathy of prematurity: a reappraisal of published trials. J Pediatr 131:844–850CrossRefPubMedGoogle Scholar
  183. Reese ABKM, Owens WC (1953) A classification of retrolental fibroplasia. Am J Ophthalmol 36:1333–1335CrossRefGoogle Scholar
  184. Reisner DS, Hansen RM, Findl O, Petersen RA, Fulton AB (1997) Dark-adapted thresholds in children with histories of mild retinopathy of prematurity. Invest Ophthalmol Vis Sci 38:1175–1183PubMedGoogle Scholar
  185. Repka MX, Palmer EA, Tung B (2000) Involution of retinopathy of prematurity. Cryotherapy for retinopathy of prematurity cooperative group. Arch Ophthalmol 118:645–649PubMedCrossRefGoogle Scholar
  186. Repka MX, Tung B, Good WV, Shapiro M, Capone A Jr, Baker JD, Barr CC, Phelps DL, van Heuven WA (2006) Outcome of eyes developing retinal detachment during the early treatment for retinopathy of prematurity study (etrop). Arch Ophthalmol 124:24–30PubMedCrossRefGoogle Scholar
  187. Reynolds JD, Dobson V, Quinn GE, Fielder AR, Palmer EA, Saunders RA, Hardy RJ, Phelps DL, Baker JD, Trese MT, Schaffer D, Tung B (2002) Evidence-based screening criteria for retinopathy of prematurity: natural history data from the cryo-rop and light-rop studies. Arch Ophthalmol 120:1470–1476PubMedCrossRefGoogle Scholar
  188. Rezai KA, Eliott D, Ferrone PJ, Kim RW (2005) Near confluent laser photocoagulation for the treatment of threshold retinopathy of prematurity. Arch Ophthalmol 123:621–626PubMedCrossRefGoogle Scholar
  189. Rivera JC, Sitaras N, Noueihed B, Hamel D, Madaan A, Zhou T, Honore JC, Quiniou C, Joyal JS, Hardy P, Sennlaub F, Lubell W, Chemtob S (2013) Microglia and interleukin-1beta in ischemic retinopathy elicit microvascular degeneration through neuronal semaphorin-3a. Arterioscler Thromb Vasc Biol 33:1881–1891PubMedCrossRefGoogle Scholar
  190. Roohipoor R, Karkhaneh R, Riazi-Esfahani M, Ghasemi F, Nili-Ahmadabadi M (2009) Surgical management in advanced stages of retinopathy of prematurity; our experience. J Ophthalmic Vis Res 4:185–190PubMedPubMedCentralGoogle Scholar
  191. Rubaltelli DM, Hirose T (2008) Retinopathy of prematurity update. Int Ophthalmol Clin 48:225–235PubMedCrossRefGoogle Scholar
  192. SanGiovanni JP, Chew EY (2005) The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. Prog Retin Eye Res 24:87–138PubMedCrossRefGoogle Scholar
  193. Sapieha P, Sirinyan M, Hamel D, Zaniolo K, Joyal JS, Cho JH, Honore JC, Kermorvant-Duchemin E, Varma DR, Tremblay S, Leduc M, Rihakova L, Hardy P, Klein WH, Mu X, Mamer O, Lachapelle P, Di Polo A, Beausejour C, Andelfinger G, Mitchell G, Sennlaub F, Chemtob S (2008) The succinate receptor gpr91 in neurons has a major role in retinal angiogenesis. Nat Med 14:1067–1076PubMedPubMedCentralCrossRefGoogle Scholar
  194. Sato T, Wada K, Arahori H, Kuno N, Imoto K, Iwahashi-Shima C, Kusaka S (2012) Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol 153:327–333 e321CrossRefPubMedGoogle Scholar
  195. Saugstad OD, Aune D (2014) Optimal oxygenation of extremely low birth weight infants: a meta-analysis and systematic review of the oxygen saturation target studies. Neonatology 105:55–63CrossRefPubMedGoogle Scholar
  196. Saunders RA, Donahue ML, Christmann LM, Pakalnis AV, Tung B, Hardy RJ, Phelps DL (1997) Racial variation in retinopathy of prematurity. The cryotherapy for retinopathy of prematurity cooperative group. Arch Ophthalmol 115:604–608PubMedCrossRefGoogle Scholar
  197. Schaffer DB, Johnson L, Quinn GE, Weston M, Bowen FW Jr (1985) Vitamin e and retinopathy of prematurity. Follow-up at one year. Ophthalmology 92:1005–1011PubMedCrossRefGoogle Scholar
  198. Schaffer DB, Palmer EA, Plotsky DF, Metz HS, Flynn JT, Tung B, Hardy RJ (1993) Prognostic factors in the natural course of retinopathy of prematurity. The cryotherapy for retinopathy of prematurity cooperative group. Ophthalmology 100:230–237PubMedCrossRefGoogle Scholar
  199. Screening examination of premature infants for retinopathy of prematurity. Pediatrics 117:572–576 (2006)Google Scholar
  200. Sears JE, Sonnie C (2007) Anatomic success of lens-sparing vitrectomy with and without scleral buckle for stage 4 retinopathy of prematurity. Am J Ophthalmol 143:810–813PubMedCrossRefGoogle Scholar
  201. Shah PK, Narendran V, Tawansy KA, Raghuram A, Narendran K (2007) Intravitreal bevacizumab (avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity. Indian J Ophthalmol 55:75–76PubMedCrossRefGoogle Scholar
  202. Shalev B, Farr AK, Repka MX (2001) Randomized comparison of diode laser photocoagulation versus cryotherapy for threshold retinopathy of prematurity: seven-year outcome. Am J Ophthalmol 132:76–80PubMedCrossRefGoogle Scholar
  203. Shao Z, Dorfman AL, Seshadri S, Djavari M, Kermorvant-Duchemin E, Sennlaub F, Blais M, Polosa A, Varma DR, Joyal JS, Lachapelle P, Hardy P, Sitaras N, Picard E, Mancini J, Sapieha P, Chemtob S (2011) Choroidal involution is a key component of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 52:6238–6248PubMedCrossRefGoogle Scholar
  204. Shastry BS, Pendergast SD, Hartzer MK, Liu X, Trese MT (1997) Identification of missense mutations in the norrie disease gene associated with advanced retinopathy of prematurity. Arch Ophthalmol 115:651–655PubMedCrossRefGoogle Scholar
  205. Silvers KM, Gibson AT, Powers HJ (1994) High plasma vitamin c concentrations at birth associated with low antioxidant status and poor outcome in premature infants. Arch Dis Child Fetal Neonatal Ed 71:F40–F44PubMedPubMedCentralCrossRefGoogle Scholar
  206. Silvers KM, Gibson AT, Russell JM, Powers HJ (1998) Antioxidant activity, packed cell transfusions, and outcome in premature infants. Arch Dis Child Fetal Neonatal Ed 78:F214–F219PubMedPubMedCentralCrossRefGoogle Scholar
  207. Sluis KB, Inder T, Wilkinson A et al (1996) Plasma and endotracheal vitamin c concentrations in premature infants: relationship to outcome measures. In: Proceedings of the 14th annual congress of the Australian Perinatal Society [abstract]Google Scholar
  208. Smiddy WE, Loupe DN, Michels RG, Enger C, Glaser BM, de Bustros S (1989) Refractive changes after scleral buckling surgery. Arch Ophthalmol 107:1469–1471PubMedCrossRefGoogle Scholar
  209. Smith LE (2004) Pathogenesis of retinopathy of prematurity. Growth Horm IGF Res 14(Suppl A):S140–S144PubMedCrossRefGoogle Scholar
  210. Smith BT, Tasman WS (2005) Retinopathy of prematurity: late complications in the baby boomer generation (1946–1964). Trans Am Ophthalmol Soc 103:225–234, discussion 234–226PubMedPubMedCentralGoogle Scholar
  211. Smith LE, Wesolowski E, McLellan A, Kostyk SK, D’Amato R, Sullivan R, D’Amore PA (1994) Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 35:101–111PubMedGoogle Scholar
  212. Sola A, Rogido MR, Deulofeut R (2007) Oxygen as a neonatal health hazard: call for detente in clinical practice. Acta Paediatr 96:801–812PubMedPubMedCentralCrossRefGoogle Scholar
  213. Stone J, Itin A, Alon T, Pe’er J, Gnessin H, Chan-Ling T, Keshet E (1995) Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (vegf) expression by neuroglia. J Neurosci 15:4738–4747CrossRefPubMedGoogle Scholar
  214. Streeter ML, Rosso P (1981) Transport mechanisms for ascorbic acid in the human placenta. Am J Clin Nutr 34:1706–1711PubMedCrossRefGoogle Scholar
  215. Subhani M, Combs A, Weber P, Gerontis C, DeCristofaro JD (2001) Screening guidelines for retinopathy of prematurity: the need for revision in extremely low birth weight infants. Pediatrics 107:656–659PubMedCrossRefGoogle Scholar
  216. Sylvester CL (2008) Retinopathy of prematurity. Semin Ophthalmol 23:318–323PubMedCrossRefGoogle Scholar
  217. Tadesse M, Dhanireddy R, Mittal M, Higgins RD (2002) Race, Candida sepsis, and retinopathy of prematurity. Biol Neonate 81:86–90PubMedCrossRefGoogle Scholar
  218. Tasman W, Patz A, McNamara JA, Kaiser RS, Trese MT, Smith BT (2006) Retinopathy of prematurity: the life of a lifetime disease. Am J Ophthalmol 141:167–174PubMedCrossRefGoogle Scholar
  219. Terry T (1942) Extreme prematurity and fibroplastic overgrowth of persistent vascular sheath behind each crystalline lens. I. Preliminary report. Am J Ophthalmol 25:203–204CrossRefGoogle Scholar
  220. Terry T (1943) Fibroblastic overgrowth of persistent tunica vasculosa lentis in premature infants. II. Report of cases–clinical aspects. Arch Ophthalmol 29:36–53CrossRefGoogle Scholar
  221. The international classification of retinopathy of prematurity revisited (2005) Arch Ophthalmol 123:991–999Google Scholar
  222. Tin W, Milligan DW, Pennefather P, Hey E (2001) Pulse oximetry, severe retinopathy, and outcome at one year in babies of less than 28 weeks gestation. Arch Dis Child Fetal Neonatal Ed 84:F106–F110PubMedPubMedCentralCrossRefGoogle Scholar
  223. Tokunaga CC, Mitton KP, Dailey W, Massoll C, Roumayah K, Guzman E, Tarabishy N, Cheng M, Drenser KA (2014) Effects of anti-vegf treatment on the recovery of the developing retina following oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 55:1884–1892PubMedCrossRefGoogle Scholar
  224. Trese MT (1994) Scleral buckling for retinopathy of prematurity. Ophthalmology 101:23–26PubMedCrossRefGoogle Scholar
  225. Tsukahara Y, Honda S, Imai H, Kondo N, Fujii S, Yokoyama N, Hirata A, Kawaji T, Fukushima M, Tanihara H, Negi A (2007) Autologous plasmin-assisted vitrectomy for stage 5 retinopathy of prematurity: a preliminary trial. Am J Ophthalmol 144:139–141PubMedCrossRefGoogle Scholar
  226. Vanderveen DK, Mansfield TA, Eichenwald EC (2006a) Lower oxygen saturation alarm limits decrease the severity of retinopathy of prematurity. J AAPOS 10:445–448PubMedCrossRefGoogle Scholar
  227. VanderVeen DK, Coats DK, Dobson V, Fredrick D, Gordon RA, Hardy RJ, Neely DE, Palmer EA, Steidl SM, Tung B, Good WV (2006b) Prevalence and course of strabismus in the first year of life for infants with prethreshold retinopathy of prematurity: findings from the early treatment for retinopathy of prematurity study. Arch Ophthalmol 124:766–773PubMedCrossRefGoogle Scholar
  228. VanderVeen DK, Bremer DL, Fellows RR, Hardy RJ, Neely DE, Palmer EA, Rogers DL, Tung B, Good WV (2011) Prevalence and course of strabismus through age 6 years in participants of the early treatment for retinopathy of prematurity randomized trial. J AAPOS 15:536–540PubMedPubMedCentralCrossRefGoogle Scholar
  229. Varughese S, Gilbert C, Pieper C, Cook C (2008) Retinopathy of prematurity in South Africa: an assessment of needs, resources and requirements for screening programmes. Br J Ophthalmol 92:879–882PubMedCrossRefGoogle Scholar
  230. Vision for children. A global overview of blindness, childhood and vision 2020: The right to sight. World health organization (who) and the international agency for the prevention of blindness (iapb). www.V2020.Org
  231. Wallace DK, Kylstra JA, Greenman DB, Freedman SF (1998) Significance of isolated neovascular tufts (“popcorn”) in retinopathy of prematurity. J AAPOS 2:52–56PubMedCrossRefGoogle Scholar
  232. Wallace DK, Veness-Meehan KA, Miller WC (2007) Incidence of severe retinopathy of prematurity before and after a modest reduction in target oxygen saturation levels. J AAPOS 11:170–174PubMedCrossRefGoogle Scholar
  233. Wang J, Ren X, Shen L, Yanni SE, Leffler JN, Birch EE (2013) Development of refractive error in individual children with regressed retinopathy of prematurity. Invest Ophthalmol Vis Sci 54:6018–6024PubMedPubMedCentralCrossRefGoogle Scholar
  234. Wang SK, Callaway NF, Wallenstein MB, Henderson MT, Leng T, Moshfeghi DM (2015) Sundrop: six years of screening for retinopathy of prematurity with telemedicine. Can J Ophthalmol 50:101–106PubMedCrossRefGoogle Scholar
  235. Wheatley CM, Dickinson JL, Mackey DA, Craig JE, Sale MM (2002) Retinopathy of prematurity: recent advances in our understanding. Br J Ophthalmol 86:696–700PubMedPubMedCentralCrossRefGoogle Scholar
  236. Wilkinson AR, Haines L, Head K, Fielder AR (2008) Uk retinopathy of prematurity guideline. Early Hum Dev 84:71–74PubMedCrossRefGoogle Scholar
  237. Wilkinson AR, Haines L, Head K, Fielder AR (2009) Uk retinopathy of prematurity guideline. Eye (Lond) 23:2137–2139CrossRefGoogle Scholar
  238. Woo SJ, Park KH, Lee SY, Ahn SJ, Ahn J, Oh KJ, Ryu A (2013) The relationship between cord blood cytokine levels and perinatal factors and retinopathy of prematurity: a gestational age-matched case-control study. Invest Ophthalmol Vis Sci 54:3434–3439PubMedCrossRefGoogle Scholar
  239. Wright KW, Sami D, Thompson L, Ramanathan R, Joseph R, Farzavandi S (2006) A physiologic reduced oxygen protocol decreases the incidence of threshold retinopathy of prematurity. Trans Am Ophthalmol Soc 104:78–84PubMedPubMedCentralGoogle Scholar
  240. Wu C, Petersen RA, VanderVeen DK (2006) Retcam imaging for retinopathy of prematurity screening. J AAPOS 10:107–111PubMedCrossRefGoogle Scholar
  241. Wu C, Lofqvist C, Smith LE, VanderVeen DK, Hellstrom A (2012) Importance of early postnatal weight gain for normal retinal angiogenesis in very preterm infants: a multicenter study analyzing weight velocity deviations for the prediction of retinopathy of prematurity. Arch Ophthalmol 130:992–999PubMedPubMedCentralCrossRefGoogle Scholar
  242. Wu WC, Shih CP, Wang NK, Lien R, Chen YP, Chao AN, Chen KJ, Chen TL, Hwang YS, Lai CC, Huang CY, Tsai S (2013a) Choroidal thickness in patients with a history of retinopathy of prematurity. JAMA Ophthalmol 131:1451–1458PubMedCrossRefGoogle Scholar
  243. Wu WC, Kuo HK, Yeh PT, Yang CM, Lai CC, Chen SN (2013b) An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in taiwan. Am J Ophthalmol 155:150–158 e151PubMedCrossRefGoogle Scholar
  244. Yalin Imamoglu E, Gunay M, Gursoy T, Imamoglu S, Balci Ekmekci O, Celik G, Karatekin G, Ovali F (2014) Effect of laser photocoagulation on plasma levels of vegf-a, vegfr-2, and tie2 in infants with retinopathy of prematurity. J AAPOS 18:466–470PubMedCrossRefGoogle Scholar
  245. Yamashita Y (1972) Studies on retinopathy of prematurity. III. Cryocautery for retinopathy of prematurity. Jpn J Clin Ophthalmol 26:385–393Google Scholar
  246. Yanamandra K, Napper D, Pramanik A, Bocchini JA Jr, Dhanireddy R (2010) Endothelial nitric oxide synthase genotypes in the etiology of retinopathy of prematurity in premature infants. Ophthalmic Genet 31:173–177PubMedCrossRefGoogle Scholar
  247. Yang CS, Wang AG, Sung CS, Hsu WM, Lee FL, Lee SM (2010) Long-term visual outcomes of laser-treated threshold retinopathy of prematurity: a study of refractive status at 7 years. Eye (Lond) 24:14–20CrossRefGoogle Scholar
  248. Yang CS, Wang AG, Shih YF, Hsu WM (2013) Astigmatism and biometric optic components of diode laser-treated threshold retinopathy of prematurity at 9 years of age. Eye (Lond) 27:374–381CrossRefGoogle Scholar
  249. Yokoi T, Yokoi T, Kobayashi Y, Hiraoka M, Nishina S, Azuma N (2009) Evaluation of scleral buckling for stage 4a retinopathy of prematurity by fluorescein angiography. Am J Ophthalmol 148:544–550 e541PubMedCrossRefGoogle Scholar
  250. Yonemura D, Aoki T, Tsuzuki K (1962) Electroretinogram in diabetic retinopathy. Arch Ophthalmol 68:19–24PubMedCrossRefGoogle Scholar
  251. Yu DY, Alder VA, Cringle SJ, Su EN, Burns M (1998) Intraretinal oxygen distribution in urethane-induced retinopathy in rats. Am J Physiol 274:H2009–H2017PubMedGoogle Scholar
  252. Zhang M, Malik AB, Rehman J (2014) Endothelial progenitor cells and vascular repair. Curr Opin Hematol 21:224–228PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • José Carlos Rivera
    • 1
    • 2
  • Elsa Duchemin-Kermorvant
    • 3
  • Allison Dorfman
    • 4
  • Tianwei Ellen Zhou
    • 1
  • Luis H. Ospina
    • 1
  • Sylvain Chemtob
    • 1
    • 2
  1. 1.Departments of Pediatrics, Ophthalmology and PharmacologyCentre Hospitalier, Universitaire Sainte-Justine, Research CenterMontréalCanada
  2. 2.Department of OphthalmologyMaisonneuve-Rosemont Hospital Research CenterMontréalCanada
  3. 3.INSERM UMRS1138, Centre de Recherche des CordeliersParisFrance
  4. 4.Department of Ophthalmology/NeurologyMcGill University-Montreal Children’s Hospital Research InstituteMontrealCanada

Personalised recommendations